Company: Gilead Sciences, Inc.
Ticker: GILD
Form: 10-K
Filed: 2026-02-24
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Gilead Sciences, Inc.'s operating cash flow in fiscal year 2025?
Question Type: value_lookup

Concept: NetCashProvidedByUsedInOperatingActivities
Answer (Numeric): 10019.0
Answer (Display): $10,019 million
Unit: USD millions

Evidence:
[{"chunk_id": "160", "equivalent_chunk_ids": ["160"], "section": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "supports": ["main"], "text": "Year Ended December 31,\n(in millions)\nOperating Activities:\nNet income\n8,510\n5,613\nAdjustments to reconcile Net income to Net cash provided by operating activities:\nDepreciation expense\nAmortization expense\n2,390\n2,386\n2,339\nStock-based compensation expense\nDeferred income taxes\n1,844\nNet (gain) loss from equity securities\nAcquired in-process research and development expenses\n1,024\n4,663\n1,155\nIn-process research and development impairments\n4,180\nOther, net\nChanges in operating assets and liabilities:\nAccounts receivable, net\nInventories\n1,036\nPrepaid expenses and other\nAccounts payable\nIncome tax assets and liabilities, net\n2,108\n1,768\nAccrued and other liabilities\nNet cash provided by operating activities\n10,019\n10,828\n8,006\nInvesting Activities:\nPurchases of marketable debt securities\n3,939\n1,930\nProceeds from sales of marketable debt securities\n2,265\nProceeds from maturities of marketable debt securities\n1,334\nAcquisitions, including in-process research and development, net of cash acquired\n1,070\n4,840\n1,152\nPurchases of equity securities\nPurchases of property, plant and equipment\nOther investing activities, net\nNet cash used in investing activities\n4,793\n3,449\n2,265\nFinancing Activities:\nProceeds from debt financing, net of issuance costs\n3,464\n1,980\nProceeds from issuances of common stock\nRepurchases of common stock under repurchase programs\n1,922\n1,150\n1,000\nRepayments of debt and other obligations\n1,788\n1,970\n2,250\nPayments of dividends\n4,003\n3,918\n3,809\nOther financing activities, net\nNet cash used in financing activities\n7,745\n3,433\n5,125\nEffect of exchange rate changes on cash and cash equivalents\nNet change in cash and cash equivalents\n2,428\n3,906\nCash and cash equivalents at beginning of period\n9,991\n6,085\n5,412\nCash and cash equivalents at end of period\n7,564\n9,991\n6,085\nSee accompanying notes.\nGILEAD SCIENCES, INC."}]

Derivation: